Welchol Litigation Settlement Allows Impax to Launch Generic Tablet in 2015

Impax Laboratories Inc. said June 30 it had settled patent litigation with Daiichi Sankyo Inc. and Genzyme Corp. over its proposed generic version of Welchol (colesevelam HCl) tablets and Welchol oral suspension products (Daiichi Sankyo Inc. v. Impax Laboratories Inc.).

Under the settlement, Impax will be allowed to launch its generic tablet product on March 2, 2015, or earlier, under certain circumstances. Impax said the settlement also provides for the launch of the oral suspension products, but those terms were not disclosed. The patent infringement litigation will be dismissed as a result of the settlement.

Genzyme developed Welchol, ...